stockrowMacroGenics, Inc.
MGNXMacroGenics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $149.5 million, roughly unchanged from fiscal 2024.
- Revenue
- +47.6%
- EPS
- +154.4%
- Free cash flow
- +12.9%
Quarter to June 2026, against a year earlier
Follow MGNX
Alert me
MacroGenics, Inc. (MGNX) Return on invested capital
MacroGenics, Inc.'s return on invested capital over the twelve months to 30 June 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from −1,068.5% (fiscal 2018) to 0.00% (fiscal 2025) — the current reading is the highest in ten years. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 350.76 |
| FY2020 | −350.8% | 393.86 |
| FY2019 | −744.6% | 323.92 |
| FY2018 | −1,068.5% | (1,068.54) |
| FY2017 | 0.00% | 0.00 |
| FY2016 | 0.00% | 0.00 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| INO Inovio Pharmaceuticals, Inc. compare | 0.00% |
| MSLE Satellos Bioscience Inc. compare | 0.00% |
| STRO Sutro Biopharma, Inc. compare | 0.00% |
| ANTX AN2 Therapeutics, Inc. compare | 0.00% |
| ADAG Adagene Inc. Sponsored ADR compare | 0.00% |
| MGNX MacroGenics, Inc. | 0.00% |
| NGEN NervGen Pharma Corp. compare | 0.00% |
| SION Sionna Therapeutics, Inc. compare | −125.0% |
| VRXA Veraxa Biotech AG compare | — |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)